Safety of biologics in inflammatory bowel disease patients with COVID-19

BACKGROUND: Patients with Inflammatory bowel disease (IBD) remain highly concerned that either their disease or medications—namely, biologics—may increase the risk of severe coronavirus-2019 (COVID-19). We aimed to assess the safety of biologics in Inflammatory bowel disease (IBD) patients with COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Weissman, Simcha, Aziz, Muhammad, Smith, Wade-Lee, Elias, Sameh, Swaminath, Arun, Feuerstein, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205311/
https://www.ncbi.nlm.nih.gov/pubmed/34131784
http://dx.doi.org/10.1007/s00384-021-03977-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205311/
https://www.ncbi.nlm.nih.gov/pubmed/34131784
http://dx.doi.org/10.1007/s00384-021-03977-9

Ejemplares similares